1. Effectiveness of N-acetylcysteine for preserving residual renal function in patients undergoing maintenance hemodialysis: multicenter randomized clinical trial
- Author
-
Mahsa Abbaszadeh, F Ahmadi, Simin Dashti Khoidaki, Effat Razeghi, Mahboob Lessan-Pezeshki, Mohammad Najafi, and Sima Maziar
- Subjects
Male ,Nephrology ,medicine.medical_specialty ,Time Factors ,Physiology ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,Administration, Oral ,Urination ,Renal function ,Iran ,030204 cardiovascular system & hematology ,Kidney ,Models, Biological ,Antioxidants ,law.invention ,Acetylcysteine ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Renal Dialysis ,law ,Physiology (medical) ,Internal medicine ,Statistical significance ,medicine ,Humans ,In patient ,Aged ,business.industry ,Middle Aged ,Intention to Treat Analysis ,Surgery ,Clinical trial ,Urodynamics ,Treatment Outcome ,Kidney Failure, Chronic ,Female ,Hemodialysis ,business ,Glomerular Filtration Rate ,medicine.drug - Abstract
To investigate the efficacy and safety of oral N-acetylcysteine (NAC) for preserving residual renal function in patients undergoing hemodialysis. Randomized, multi-center, parallel-group, open-label clinical trial (Registration No. IRCT 2014071418482N1). 54 patients who have been undergoing hemodialysis for at least 3 months and had residual urine volume >100 ml/24 h were randomly allocated to NAC or no medication. Residual renal function evaluated by (1) estimated glomerular filtration rate (GFR), (2) 24 h urine volume, and (3) renal Kt/V. GFR and Kt/V was determined at baseline and after 3 months. 24 h urine volume was measured at baseline, after 1, 2, and 3 months. Intention-to-treat analysis was performed on 47 patients (NAC = 26, control = 21). GFR in patients receiving NAC improved, whereas in the control arm a decline of 1.0 ml/min/1.73 m2 was recorded (3.59 vs. 2.11 ml/min/1.73 m2, effect size = 17.0 %, p = 0.004). For 24 h urine volume, the between-group difference after 1 month was significant (669 vs. 533 ml/24 h, effect size = 15.4 %, p = 0.004). After 3 months, 24 h urine volume in the NAC arm was on average 137 ml higher than in the control group, and the difference reached near significance (673 vs. 536 ml/24 h, p = 0.072). In the follow-up visit, Kt/V was higher in the NAC arm but the difference did not reach statistical significance (0.81 vs. 0.54, p = 0.152). Three months treatment with NAC appears to be effective in preserving renal function in patients undergoing hemodialysis and the medication is generally well-tolerated.
- Published
- 2016
- Full Text
- View/download PDF